5.51
5.51 (0%)
As of Apr 17, 2025
Jaguar Health, Inc. [JAGX]
Source:
Company Overview
Jaguar Health, Inc. is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, sustainably derived prescription medicines for people and animals with gastrointestinal (“GI”) distress, including chronic, debilitating diarrhea.
| Country | United States |
| Headquarters | san francisco, california |
| Phone Number | 415-371-8300 |
| Industry | manufacturing |
| CEO | Lisa A. Conte |
| Website | jaguarhealth.gcs-web.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $11.7 |
| Operating Profit | $-30.8 |
| Net Income | $-39.3 |
| Net Cash | $1.5 |
Profit Ratios
| Gross Margin | $9.7 |
| Operating Margin | -263.8 |
| Profit as % of Revenues | -24.8% |
| Profit as % of Assets | -75.4% |
| Profit as % of Stockholder Equity | -604.4% |
Management Effectiveness
| Return on Equity | -604.4% |
| Return on Assets | -73.5% |
| Turnover Ratio | 22.4% |
| EBITA | $-30.8 |
Balance Sheet and Cash Flow Measures
| Total Assets | $53.4 |
| Total Liabilities | $44.4 |
| Operating Cash Flow | $-29.4 |
| Investing Cash Flow | $-0.2 |
| Financing Cash Flow | $31.2 |
